Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), has announced that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement for gross proceeds of approximately US$212 million, before deducting placement agent fees and offering expenses.
Latham & Watkins LLP represented Gossamer Bio is the transaction, with a corporate team led by San Diego partner Matt Bush, with associates Shelby Harrison and Emilie McConnachie.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.